MAB.WA
Mabion S.A. [MAB.WA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MAB.WA Stock Summary
Top 10 Correlated ETFs
MAB.WA
Top 10 Correlated Stocks
MAB.WA
In the News
MAB.WA Financial details
Company Rating
-
Market Cap
267.65M
Income
58.26M
Revenue
148.1M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
248
Optionable
No
Shortable
Yes
Earnings
16 Apr 2024
P/E
5.51
Forward P/E
-
PEG
0.02
P/S
2.16
P/B
2.7
P/C
-
P/FCF
9.54
Quick Ratio
1.38
Current Ratio
1.49
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
3.6
EPS next Y
-
EPS next Q
-
EPS this Y
1100%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-17.9%
EPS Q/Q
-28.72%
-
-
-
-
SMA20
3.74%
SMA50
5.3%
SMA100
-11.88%
Inst Own
-
Inst Trans
-
ROA
25%
ROE
59%
ROC
0.39%
Gross Margin
75%
Oper. Margin
40%
Profit Margin
39%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
15.8-23.6
52W High
-52.52%
52W Low
-27.2%
RSI
60.34
Rel Volume
1.32
Avg Volume
27K
Volume
35.7K
Perf Week
9.31%
Perf Month
5%
Perf Quarter
-17.4%
Perf Half Y
-29.82%
-
-
-
-
Beta
0.972
-
-
Volatility
0.54%, 0.58%
Prev Close
-2.15%
Price
10.92
Change
-6.51%
Company Profile
- Volume Average 27K
- Market Capitalization 267.65M
- Employee 248
- CEO Mr. Krzysztof Kaczmarczyk
- Headquarters Konstantynów Lódzki,PL
- IPO Date 2010-08-10
-
Website
https://www.mabion.eu 
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
